These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 10439927)

  • 21. Angiogenesis and angiogenesis inhibitors in cancer.
    Giavazzi R; Taraboletti G
    Forum (Genova); 1999; 9(3):261-72. PubMed ID: 10504172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiogenesis: regulators and clinical applications.
    Liekens S; De Clercq E; Neyts J
    Biochem Pharmacol; 2001 Feb; 61(3):253-70. PubMed ID: 11172729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antineovascular therapy, a novel antiangiogenic approach.
    Shimizu K; Asai T; Oku N
    Expert Opin Ther Targets; 2005 Feb; 9(1):63-76. PubMed ID: 15757482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Periostin: a putative mediator involved in tumour resistance to anti-angiogenic therapy?
    Wang W; Ma JL; Jia WD; Xu GL
    Cell Biol Int; 2011 Nov; 35(11):1085-8. PubMed ID: 21999314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects.
    Battegay EJ
    J Mol Med (Berl); 1995 Jul; 73(7):333-46. PubMed ID: 8520966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
    Bozza C; Fontanella C; Buoro V; Mansutti M; Aprile G
    Expert Rev Clin Pharmacol; 2015 Mar; 8(2):251-65. PubMed ID: 25597501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of angiogenesis in solid tumours: an overview.
    Makrilia N; Lappa T; Xyla V; Nikolaidis I; Syrigos K
    Eur J Intern Med; 2009 Nov; 20(7):663-71. PubMed ID: 19818284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenesis and its targeting in rheumatoid arthritis.
    Szekanecz Z; Koch AE
    Vascul Pharmacol; 2009 Jul; 51(1):1-7. PubMed ID: 19217946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synopsis of angiogenesis inhibitors in oncology.
    Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
    Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of angiogenesis in cancers.
    Pang RW; Poon RT
    Vasc Health Risk Manag; 2006; 2(2):97-108. PubMed ID: 17319453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of angiogenesis in tumor growth and metastasis.
    Folkman J
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):15-8. PubMed ID: 12516034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular targeting and the inhibition of angiogenesis.
    Bicknell R
    Ann Oncol; 1994; 5 Suppl 4():45-50. PubMed ID: 7520262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
    van Moorselaar RJ; Voest EE
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):239-50. PubMed ID: 12431818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiogenic inhibitors: a new therapeutic strategy in oncology.
    Gasparini G; Longo R; Toi M; Ferrara N
    Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.
    Rege TA; Fears CY; Gladson CL
    Neuro Oncol; 2005 Apr; 7(2):106-21. PubMed ID: 15831230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
    Ribatti D
    Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance.
    Mander KA; Finnie JW
    Aust Vet J; 2018 Oct; 96(10):371-378. PubMed ID: 30255577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.
    Hawinkels LJ; Garcia de Vinuesa A; Ten Dijke P
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1371-83. PubMed ID: 24053899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.